Overview

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Status:
Enrolling by invitation
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC